Clinical Trial Update: Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating azacitidine or ATA in combination with pevonedistat for MDS/AML patients at impending hematological relapse.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia in Remission
• Myelodysplastic Syndromes

Drugs mentioned

• ATA
• AZACITIDINE (AZACITIDINE)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: University of Leipzig | Conditions: Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED